
Work Here?
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Industries
Industrial & Manufacturing
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$6.8M
Above
Industry Average
Funded Over
2 Rounds
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Colorectal Cancer Alliance launches online hub demystifying unexpected home delivery of screening tests. Use-at-home screening tests can detect colorectal cancer, and some can detect pre-cancerous conditions, too. Alliance & Abbott Partner to Educate and Encourage CRC Screening Adherence This Hub gives people clear, trustworthy answers so they feel confident completing their screening instead of setting it aside." - Michael Sapienza, CEO of the Colorectal Cancer Alliance WASHINGTON, DC, UNITED STATES, September 1, 2026 / EINPresswire.com / - Key Takeaways: - Colorectal cancer is the second deadliest cancer in the U.S. but has a 91% survival rate when caught early. - Health plans are increasingly mailing use-at-home screening kits, like the Cologuard (R) test, directly to eligible members to increase screening participation. - The Colorectal Cancer Alliance and Abbott have launched a new online hub to explain why people receive these kits and how to use them at crcancer.org/screenhub. Colorectal cancer (CRC) is the second deadliest cancer in the United States, yet it's also one of the most preventable and treatable, with a 91% survival rate when caught early through timely screening.* To make screening easier and more convenient, health insurance plans and preventive care programs are proactively mailing screening kits, like Cologuard, directly to members' homes once they become eligible. When these kits arrive the recipient may wonder why, or what to do next. To close that information gap, the Colorectal Cancer Alliance is partnering with Abbott, maker of the Cologuard (R) test, to launch a new online hub answering common questions about this program. The hub is designed to promote patient education and encourage screening participation to help save lives. Why Recipients Get a Kit Use-at-home screening tests can detect colorectal cancer, and some can detect pre-cancerous conditions, too, helping to save lives. Insurance companies review a member's age and health information against national screening guidelines to identify who is due for colorectal cancer screening. Kits are then sent directly to members' homes, removing the hassle of scheduling and making screening easier to complete. Use-at-home screening kits are FDA-approved medical devices - not scams or junk mail. They arrive sealed in official packaging with detailed instructions, and are offered at no extra cost as a covered health benefit. "Too often, people receive one of these test kits in the mail and simply don't know what it is or why they got it," said Michael Sapienza, CEO of the Colorectal Cancer Alliance. "That confusion can mean a delayed or missed screening that might have prevented colorectal cancer. This Hub gives people clear, trustworthy answers so they feel confident completing their screening instead of setting it aside." Who It's Intended For Use-at-home screening kits are designed for adults age 45 and older who are at average risk for colorectal cancer, meaning no symptoms and no personal or family history of conditions associated with increased CRC risk, such as precancerous polyps or inflammatory bowel disease. Anyone with CRC risk factors or active symptoms like blood in the stool should talk to their healthcare provider first, as a colonoscopy is the better next step for them. Additionally, an abnormal result from a stool-based screening test always requires a follow-up colonoscopy. "Cologuard has helped millions of people get screened for colorectal cancer from the comfort of their homes, but we know that many people still have questions when they receive a kit from their health plan," said Paul Limburg, M.D., chief medical officer, screening, Abbott's cancer diagnostics business. "By partnering with the Colorectal Cancer Alliance on this hub, we're helping to make sure people have the information they need to trust the process and take appropriate action to protect their health." To learn more about colorectal cancer risk factors, symptoms, and screening options, visit getscreened.org. About The Colorectal Cancer Alliance The Colorectal Cancer Alliance is the leading patient advocacy organization dedicated to ending colon and rectal cancers. The Alliance helps people facing the disease today, while innovating toward a future where fewer people are diagnosed and more lives are saved. Founded in 1999 and headquartered in Washington, D.C., the Alliance invests in innovation, supports patients and families, champions awareness and advocacy, and builds community to ensure no one faces this disease alone. For more information, visit colorectalcancer.org or call the helpline at (877) 422-2030. Connect with US National Times on Facebook, Instagram, X, YouTube and TikTok. * Siegel RL, Wagle NS, Star J, et al. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026;e70067. Emily Blasi Colorectal Cancer Alliance +1 202-971-9964 email US National Times here Visit US National Times on social media: LinkedIn Bluesky Instagram Facebook YouTube TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. US National Times do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Abbott's Amulet 360: A new push to reshape the $2B LAA closure market. Abbott has secured the CE Mark for its next-generation Amulet 360(TM) device, strengthening its position in the rapidly evolving left atrial appendage (LAA) closure market. The device is designed for people with atrial fibrillation (AFib) who are at risk of stroke, particularly those who may not be suitable for long-term blood-thinning therapy. Why this matters. - Market-share opportunity: Abbott CEO Robert Ford estimates the LAA closure market at approximately $2 billion, with the leading competitor holding around 90% share. - Direct competition with Watchman: Abbott's Amulet competes directly with Boston Scientific's Watchman, the current market leader. - Product differentiation: Amulet 360 is engineered to improve how the implant conforms to and seals the LAA, potentially supporting a more seamless implantation experience for physicians. - Clinical validation: The device met safety and effectiveness benchmarks in the VERITAS study, supporting the CE Mark decision. - Expansion across Europe: Abbott plans to introduce Amulet 360 across European markets in the coming weeks. Competitive landscape. The LAA closure market is becoming increasingly competitive as MedTech companies target the growing AFib population. Key players include: * Abbott - Amulet / Amulet 360 * Boston Scientific - Watchman * Medtronic - Penditure LAA Exclusion System * AtriCure - AtriClip * Edwards Lifesciences - LAA clip technology Abbott has also completed its FDA submission for Amulet 360, potentially opening another major growth opportunity in the U.S. Strategic takeaway. Amulet 360 is more than a product refresh; it represents Abbott's strategic attempt to capture share in a concentrated, high-value market. With improving clinical evidence, product innovation and growing competition, LAA closure could become an increasingly important battleground in structural heart and electrophysiology. #Abbott #BostonScientific #Medtronic #AtriCure #EdwardsLifesciences #MedTech #Cardiology #StructuralHeart #AtrialFibrillation #AFib #LAAClosure #MedicalDevices #Healthcare #MarketIntelligence #MedTechInnovation
Abbott has launched Similac 360 Total Care Made With Whole Milk, the first commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. The product combines whole milk with five human milk oligosaccharides, prebiotics structurally identical to those found in breast milk, designed to support babies' immune systems, brain development, and digestive health. The formula is being offered at prices similar to the per-feeding cost of Similac's powdered formulas. It is available at Target and Amazon from today, with rollout to Walmart and other retailers planned in coming weeks. Unlike powdered formula, the ready-to-feed liquid requires no preparation and is commercially sterile, meaning it has undergone additional heat treatment to eliminate potentially harmful microorganisms. The product will be manufactured at Abbott's US facility.
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula. * New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses - making it Similac's closest formula to breast milk * Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula * Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers. ABBOTT PARK, Ill., August 31, 2026 - Parents looking for an infant formula made with whole milk now have a new option. Abbott today announced the launch of Similac(R) 360 Total Care Made With Whole Milk - the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. This new formula is available at launch pricing similar to the per-feeding cost of Similac 360 Total Care powdered infant formulas. Infant formulas made with whole milk have become a popular choice because they provide a fat blend that more closely resembles the fats found in breast milk. Similac 360 Total Care Made With Whole Milk is Similac's closest formula to breast milk. It combines whole milk and an exclusive blend of five human milk oligosaccharides (HMOs), which are prebiotics structurally identical to five of those found in breast milk. This formula is designed to help support a baby's immune system, brain development, and digestive health. Similac 360 Total Care Made With Whole Milk is also non-GMO[i] and does not contain artificial growth hormones[ii], corn syrup or palm olein oil. "Parents have been asking for more whole milk options, and we wanted to give them something they couldn't get anywhere else," said Misha Pardubicka-Jenkins, Abbott's U.S. vice president and general manager for pediatric nutrition. "We decided on a liquid-only approach to give families the benefits of whole milk, the convenience of a formula that's ready when baby is, and the reassurance that comes with a commercially sterile liquid formula. And through launch, we'll make it accessible to more families by offering it at powder-like prices." Abbott made the decision to bring this new formula to American families in a commercially sterile, liquid offering only. This gives parents the choice of formula made with whole milk in a convenient, ready-to-feed format, and it provides the inherent peace of mind that comes with liquid infant formulas. Unlike powdered formula, ready-to-feed liquid formula requires no preparation. Parents can simply open and feed, whether at home, while traveling or during overnight feedings. Whether powder or liquid, parents can use all Similac formulas confidently. "As a pediatrician, I've spent decades helping parents navigate infant feeding, so I know how meaningful it is to find a formula option parents feel confident choosing," said Karyn Wulf, M.D., pediatrician and senior medical director in Abbott's nutrition division. "All Similac formulas start with high-quality ingredients that provide the essential nutrition babies need to grow and develop. Ready-to-feed infant formulas offer parents convenience because they require no mixing and the reassurance that comes with a commercially sterile liquid." Availability and pricing Starting today, Similac 360 Total Care Made With Whole Milk is available at Target and Amazon. Over the coming weeks, customers can find the liquid formula at Walmart and additional retail and club locations, grocers and pharmacy chains. While liquid infant formulas typically cost more than powdered, Abbott is launching the 8 fl oz and 32 fl oz sizes of Similac 360 Total Care Made With Whole Milk at prices similar to the per-feeding cost of Similac 360 Total Care powdered infant formulas. This gives more families access to the convenience of ready-to-feed formula at pricing similar to powder. Similac 360 Total Care Made With Whole Milk joins Abbott's extensive portfolio of infant formulas and expands feeding options for families seeking a formula made with whole milk. Each batch of Similac 360 Total Care Made With Whole Milk will be produced at Abbott's own manufacturing facility in the U.S. Frequently Asked Questions: Is Abbott discontinuing its original Similac 360 Total Care liquid infant formula? No. For parents who prefer the original Similac 360 Total Care formula, that product will remain in 2 fl oz and 8 fl oz ready-to-feed format. Nothing changes in its original Similac 360 Total Care powdered formulas, which will still be available at various sizes and price points. What does it mean for an infant formula to be commercially sterile? While all formulas, including powdered formulas, are manufactured to eliminate potentially harmful microorganisms, commercial sterility means a liquid infant formula has undergone an additional, carefully controlled, validated heat treatment process designed to eliminate spores of potentially harmful microorganisms, particularly Clostridium spores. The nutritional quality of all Abbott's liquid, ready-to-feed infant formulas is maintained throughout the heat treatment process. All of Abbott's liquid, ready-to-feed infant formulas are commercially sterile. Why are liquid, ready-to-feed infant formulas considered a safer formula option for certain babies? Ready-to-feed liquid formulas are often used for convenience, especially in those late-night hours when mixing formula is less than ideal. However, both FDA and CDC advise parents of infants under two months of age and those with weakened immune systems should also consider feeding a commercially sterile liquid formula for infants not receiving breast milk. Are powdered infant formulas safe? Yes. Parents can continue using Similac powdered infant formulas with confidence, knowing that MultiVu design its manufacturing processes to help prevent the presence and growth of potentially harmful bacteria across both liquid and powder formula production. All of Abbott's powdered infant formulas are manufactured under rigorous quality and safety controls and meet or exceed industry regulations for infant formula testing. About Similac(R) Similac has been feeding babies for more than 100 years. Backed by Abbott's science and research, Similac is committed to supporting parents with high-quality infant nutrition that meets a wide variety of babies' needs and parents' preferences. Connect with MultiVu at Similac.com and on Facebook, Instagram, YouTube and TikTok. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. Connect with MultiVu at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. Abbott Media: Michelle Schott, (614) 286-4727 or [email protected] Erin Stan, (614) 214-9268 or [email protected] Abbott Financial: Randy Blakley, (224) 507-9879 [i] *Ingredients not genetically engineered [ii] Milk ingredients are derived from milk of non-rbST-treated cows, which is not different from milk of rbST-treated cows.
FDA authorizes first wearable to track both ketones and blood sugar. by Ellyn Vohnoutka This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: fact-checked reputable news agency People with diabetes can now get an early warning when a dangerous complication starts to build in their bodies. The U.S. Food and Drug Administration (FDA) on Tuesday authorized the first wearable sensor that continuously tracks ketones - chemicals the body makes when it burns fat instead of sugar for fuel. It is also the first device anywhere to monitor ketones and blood sugar at the same time, the FDA said. When ketones climb too high, they can cause diabetic ketoacidosis, or DKA. The American Diabetes Association warns that DKA can worsen within hours and lead to coma or death if it goes untreated. Hospital admissions for DKA have risen 55% over the past decade, according to Abbott, which makes the device. Early symptoms are often mistaken for a stomach bug or another common infection, which delays care. Most people also do not keep a blood ketone meter at home. "Knowing that ketone levels are rising, and having that information in real time, around the clock, can be the difference between early intervention and a life-threatening emergency," said Dr. Michelle Tarver, who directs the FDA's Center for Devices and Radiological Health. The sensor, called Libre Duo 10 Day, sticks to the skin and reads both ketones and glucose in the fluid just beneath the surface every minute, day and night. Readings travel wirelessly to a smartphone app that shows current levels and whether they are trending up or down. The app sounds an alert when ketones reach a concerning level. Until now, people had to check ketones separately using blood or urine tests. Those tests capture a single moment and cannot show whether levels are climbing or falling. "As a physician, I see how quickly DKA can develop - and how often early warning signs or opportunities to measure ketones are missed," said Dr. Jennifer Sherr, a pediatric endocrinologist at Yale School of Medicine. About 40.1 million Americans have diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). The new device is authorized for anyone with diabetes ages 2 and older. Abbott says it is aimed at people at higher risk of elevated ketones, including those who take insulin or glucose-lowering medications. Six studies enrolling more than 600 people supported the decision, the FDA said. The device accurately tracked meaningful changes in ketone levels across the full 10-day wear period and flagged elevated ketones before DKA took hold. Abbott plans to launch the sensor in the United States later this year. The company is also working to connect it with automated insulin delivery systems. The FDA cautions that ketone readings should always be considered alongside glucose numbers and a person's symptoms. Who's behind this story? MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile Citation : FDA authorizes first wearable to track both ketones and blood sugar (2026, August 29) retrieved 31 August 2026 from https://medicalxpress.com/news/2026-08-fda-authorizes-wearable-track-ketones.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
Find jobs on Simplify and start your career today